Please assess the completion status of the following clinical trial:

Trial Title: A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Is of American Society of Anesthesiologists (ASA) class 1 - 3;~* Is at least 20 years but under 65 years of age;~* Caucasian participants;~* Is scheduled for elective surgery requiring muscle relaxation in supine position and under sevoflurane anesthesia with an anticipated duration of about 1.5-3 hours;~* Has given written informed consent.~Exclusion criteria:~* Participants in whom a difficult intubation because of anatomical malformations was expected;~* Is known or suspected to have neuromuscular disorders impairing neuromuscular blocking (NMB) and/or significant renal dysfunction (for example a creatinine level \> 1.6 mg/dl) and/or severe hepatic dysfunction.~* Is known or suspected to have a (family) history of malignant hyperthermia;~* Is known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;~* Is receiving medication expected to interfere with the rocuronium or vecuronium given in this trial, based on the dose and time of administration;~* Females who were pregnant;~* Females of childbearing potential not using birth control or using only oral contraception as birth control;~* Was breast-feeding;~* Has already participated in P05971, or in another trial with sugammadex;~* Has participated in another clinical trial, not preapproved by the Sponsor, within 6 months of entering into P05971.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rocuronium + Placebo (Type: PLACEBO_COMPARATOR): After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
- Rocuronium + 0.5 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
- Rocuronium + 1.0 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
- Rocuronium + 2.0 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
- Rocuronium + 4.0 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
- Vecuronium + Placebo (Type: PLACEBO_COMPARATOR): After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
- Vecuronium + 0.5 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
- Vecuronium + 1.0 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
- Vecuronium + 2.0 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
- Vecuronium + 4.0 mg/kg Sugammadex (Type: EXPERIMENTAL): After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete